Skip to content
Inciteful Med

Symptoms and Disease Progression of Huntington Disease

Last updated:

Huntington's disease progresses through a triad of symptoms affecting mood, thinking, and movement. Psychiatric and cognitive changes like apathy often appear years before physical symptoms like chorea. Doctors track this journey using specific staging systems like the HD-ISS.

Key Takeaways

  • • Huntington's disease involves a triad of motor, cognitive, and psychiatric symptoms.
  • • Changes in mood, thinking, and motivation (apathy) often appear years before physical movement issues.
  • • Physical symptoms typically evolve from involuntary jerky movements (chorea) to stiffness and slowed movements (rigidity).
  • • Doctors use the UHDRS exam and the HD-ISS staging system to track disease progression over time.
  • • Juvenile Huntington's Disease (onset before age 20) progresses rapidly and presents with stiffness and seizures rather than chorea.

Huntington’s Disease (HD) is often described as having a “triad” of symptoms: motor (movement), cognitive (thinking), and psychiatric (mood) [1]. While every person’s journey is unique, the disease typically follows a predictable path of progression that often begins long before a doctor can see physical signs of the disease [2][3].

The Progression Triad

1. Psychiatric and Cognitive Symptoms (The Early Signs)

For many people, the first signs of HD are not movement-related. Instead, they involve changes in mood and thinking that can appear years, or even decades, before physical symptoms [2][1].

  • Apathy: This is one of the most common early symptoms [4]. It is not “laziness”; it is a medical symptom where the brain has difficulty starting activities or feeling motivation [5][6].
  • Executive Dysfunction: You may find it harder to multitask, organize a schedule, or “filter” your thoughts [7][8].
  • Mood Changes: Depression, anxiety, and irritability are frequent and can fluctuate throughout the disease [2].

2. Motor Symptoms (The Shift from “Dance” to “Stiffness”)

Physical symptoms in adult HD usually evolve through two distinct phases:

  • Chorea (Early to Middle Stages): These are jerky, random, involuntary movements that may look like fidgeting or a “dance” [1].
  • Rigidity and Bradykinesia (Late Stages): As the disease progresses, the “extra” movements often fade and are replaced by rigidity (stiffness) and bradykinesia (slowness of movement) [9][10].

How Doctors Measure Symptoms: The UHDRS

If you are already experiencing symptoms, or during a routine check-up, your doctor will use the Unified Huntington’s Disease Rating Scale (UHDRS) [11].

  • What it is: A standardized exam that checks your motor skills (movement), cognitive abilities (thinking), and behavior [11].
  • The Total Motor Score (TMS): This is the part of the test doctors use to track things like chorea (jerky movements) or balance [11][12].
  • Baseline Tracking: Even if you don’t have symptoms, a UHDRS exam can provide a “baseline” to help doctors notice tiny changes over several years [12].

Understanding the HD-ISS Staging

Medical experts now use the Huntington’s Disease Integrated Staging System (HD-ISS) to describe the disease continuum. This helps researchers and doctors understand exactly where a person is in their journey [13].

Stage What it Means Key Characteristics
Stage 0 Genetic Only You have the HD gene mutation, but there are no detectable changes in the brain or body [13].
Stage 1 Early Brain Changes No symptoms are visible, but specialized scans can see early changes in brain regions like the striatum [14][15].
Stage 2 Clinical Symptoms Subtle signs of movement, mood, or cognitive changes become detectable by a doctor during an exam [13].
Stage 3 Functional Decline Symptoms begin to interfere with daily life, such as work, driving, or managing a household [14][16].

Juvenile Huntington’s Disease (JHD)

When HD begins before age 20 (usually associated with more than 60 CAG repeats), it looks very different from the adult version [17][18].

  • Stiffness over Chorea: Young people with HD rarely have the “dancing” movements (chorea). Instead, they typically experience severe stiffness, tremors, and slowness from the very beginning [9][19].
  • Seizures: Unlike adult HD, seizures are a common and specific feature of the juvenile form, affecting up to 38% of patients [19][20].
  • Rapid Progression: The disease often moves more quickly in children and teenagers than it does in adults [21][18].

Frequently Asked Questions

What are the earliest symptoms of Huntington's disease?
For many people, the first signs are not movement-related. Early symptoms often involve changes in mood and thinking, such as apathy, depression, anxiety, or difficulty organizing and multitasking. These cognitive and psychiatric signs can appear years before physical changes.
Why am I feeling apathetic with Huntington's disease?
Apathy is a very common medical symptom of Huntington's disease, not a sign of laziness. It happens because the disease affects the parts of the brain responsible for starting activities, making it difficult to feel motivation or initiate tasks.
What is the difference between chorea and rigidity in Huntington's disease?
Chorea refers to random, jerky, involuntary movements that often look like a dance and are common in the early to middle stages. As the disease progresses, these movements typically fade and are replaced by rigidity, which is severe muscle stiffness, and slowed movements.
How do doctors measure Huntington's disease progression?
Doctors use the Unified Huntington's Disease Rating Scale (UHDRS) to track changes in motor skills, thinking, and behavior. They also use the Huntington's Disease Integrated Staging System (HD-ISS) to categorize the disease from Stage 0 (gene mutation only) to Stage 3 (functional decline).
How is Juvenile Huntington's Disease different from the adult form?
When the disease begins before age 20, it often progresses much more rapidly. Instead of chorea, children and teens typically experience severe stiffness, tremors, and slowed movements from the start, and they are also more likely to experience seizures.

Questions for Your Doctor

  • • Based on the HD-ISS, which stage am I currently in (Stage 0, 1, 2, or 3)?
  • • Are the mood changes or apathy I'm experiencing typical for this stage, or could they be related to something else?
  • • I've heard chorea can turn into stiffness later on—how do we monitor for that shift in my care plan?
  • • Since cognitive changes often come first, what specific tests can we use to track my 'executive function' over time?
  • • What is my current UHDRS Total Motor Score, and how does it compare to my previous visit?

Questions for You

  • • Have my family or friends noticed me becoming more 'apathetic' or less interested in things I used to love?
  • • Am I finding it harder to multitask or organize my daily schedule than I used to?
  • • Have I noticed any small, jerky movements in my fingers or toes that I can't quite control?
  • • How has my mood changed recently—am I feeling more irritable or 'stuck' on certain thoughts?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment.

    Molnar MJ, Molnar V, Fedor M, et al.

    Frontiers in psychiatry 2021; (12()):825532 doi:10.3389/fpsyt.2021.825532.

    PMID: 35222108
  2. 2

    [Psychiatric symptoms of Huntington's disease].

    Mühlbäck A, Hoffmann R, Pozzi NG, et al.

    Der Nervenarzt 2024; (95(9)):871-884 doi:10.1007/s00115-024-01728-z.

    PMID: 39212681
  3. 3

    Delayed identification and diagnosis of Huntington's disease due to psychiatric symptoms.

    Pascu AM, Ifteni P, Teodorescu A, et al.

    International journal of mental health systems 2015; (9()):33 doi:10.1186/s13033-015-0026-6.

    PMID: 26300964
  4. 4

    Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

    Covey DP, Dantrassy HM, Yohn SE, et al.

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2018; (43(10)):2056-2063 doi:10.1038/s41386-018-0107-8.

    PMID: 29925886
  5. 5

    Huntington's disease influences employment before and during clinical manifestation: A systematic review.

    van der Zwaan KF, Mentink MDC, Jacobs M, et al.

    Parkinsonism & related disorders 2022; (96()):100-108 doi:10.1016/j.parkreldis.2022.02.022.

    PMID: 35379551
  6. 6

    Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington's Disease.

    Misiura MB, Ciarochi J, Vaidya J, et al.

    Journal of the International Neuropsychological Society : JINS 2019; (25(5)):462-469 doi:10.1017/S1355617719000067.

    PMID: 30806337
  7. 7

    Cognitive Performance and Apathy Predict Unemployment in Huntington's Disease Mutation Carriers.

    Jacobs M, Hart EP, Roos RAC

    The Journal of neuropsychiatry and clinical neurosciences 2018; (30(3)):188-193 doi:10.1176/appi.neuropsych.17070144.

    PMID: 29325477
  8. 8

    Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease.

    Andrews SC, Craufurd D, Durr A, et al.

    Neuropsychology 2018; (32(8)):958-965 doi:10.1037/neu0000479.

    PMID: 30211612
  9. 9

    Pediatric Huntington Disease Brains Have Distinct Morphologic and Metabolic Traits: the RAREST-JHD Study.

    Caligiuri ME, Tinelli E, Vizza P, et al.

    Movement disorders clinical practice 2024; (11(12)):1592-1597 doi:10.1002/mdc3.14223.

    PMID: 39367695
  10. 10

    Brain structure in juvenile-onset Huntington disease.

    Tereshchenko A, Magnotta V, Epping E, et al.

    Neurology 2019; (92(17)):e1939-e1947 doi:10.1212/WNL.0000000000007355.

    PMID: 30971481
  11. 11

    Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

    Mestre TA, Forjaz MJ, Mahlknecht P, et al.

    Movement disorders clinical practice 2018; (5(2)):111-117 doi:10.1002/mdc3.12571.

    PMID: 30363393
  12. 12

    Motor outcome measures in Huntington disease clinical trials.

    Reilmann R, Schubert R

    Handbook of clinical neurology 2017; (144()):209-225 doi:10.1016/B978-0-12-801893-4.00018-3.

    PMID: 28947119
  13. 13

    A biological classification of Huntington's disease: the Integrated Staging System.

    Tabrizi SJ, Schobel S, Gantman EC, et al.

    The Lancet. Neurology 2022; (21(7)):632-644 doi:10.1016/S1474-4422(22)00120-X.

    PMID: 35716693
  14. 14

    Applying the Huntington's Disease Integrated Staging System (HD-ISS) to Observational Studies.

    Long JD, Gantman EC, Mills JA, et al.

    Journal of Huntington's disease 2023; (12(1)):57-69 doi:10.3233/JHD-220555.

    PMID: 37092230
  15. 15

    Simple diameters, accurate stages:a practical approach to HD-ISS staging.

    Heim B, Krismer F, Hemicker G, et al.

    Journal of neurology 2025; (272(12)):760 doi:10.1007/s00415-025-13409-1.

    PMID: 41239019
  16. 16

    Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington's disease: Korean cohort data.

    Hwang YS, Oh E, Kim M, et al.

    Journal of the neurological sciences 2023; (452()):120744 doi:10.1016/j.jns.2023.120744.

    PMID: 37541133
  17. 17

    Huntington's Disease: A Report of an Interesting Case and Literature Review.

    Sharma PK, Aram A, Polaka Y, Pandian V

    Cureus 2024; (16(3)):e55443 doi:10.7759/cureus.55443.

    PMID: 38567236
  18. 18

    Clinical Review of Juvenile Huntington's Disease.

    Oosterloo M, Touze A, Byrne LM, et al.

    Journal of Huntington's disease 2024; (13(2)):149-161 doi:10.3233/JHD-231523.

    PMID: 38669553
  19. 19

    Juvenile Huntington's disease masquerading as progressive myoclonus epilepsy.

    Thakor B, Jagtap SA, Joshi A

    Epilepsy & behavior reports 2021; (16()):100470 doi:10.1016/j.ebr.2021.100470.

    PMID: 34377971
  20. 20

    Juvenile Huntington's Disease: Diagnostic and Treatment Considerations for the Psychiatrist.

    Quigley J

    Current psychiatry reports 2017; (19(2)):9 doi:10.1007/s11920-017-0759-9.

    PMID: 28168595
  21. 21

    Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.

    Fusilli C, Migliore S, Mazza T, et al.

    The Lancet. Neurology 2018; (17(11)):986-993 doi:10.1016/S1474-4422(18)30294-1.

    PMID: 30243861

This page explains Huntington disease symptoms and progression for educational purposes only. Always consult your neurologist for personalized medical advice, staging, and symptom management.

Stay up to date

Get notified when new research about Huntington disease is published.

No spam. Unsubscribe anytime.